Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Blood (2022) 140 (Supplement 1): 1346–1349.

https://doi.org/10.1182/blood-2022-168521

Published: 2022

Journal Articles

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Jakob D. Rudzki, Ulrich Jaeger, Dominik Wolf, Andreas Petzer, Richard Greil, Christina Peters, Hildegard T. Greinix, Andishe Attarbaschi, Veronika Buxhofer-Ausch, Michael Girschikofsky, Wolfgang Holter, Michael Leisch, Peter Neumeister, Peter Schlenke, Clemens A. Schmitt, Wolfgang Schwinger, Nina Worel, Philipp Wohlfarth

Blood (2022) 140 (Supplement 1): 6661–6663.

https://doi.org/10.1182/blood-2022-167603

Published: 2022

Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Blood (2022) 140 (Supplement 1): 1459–1463.

https://doi.org/10.1182/blood-2022-158024

Published: 2022

Journal Articles

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Blood (2021) 138 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2021-145401

Published: 2021

Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Blood (2021) 138 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2021-150311

Published: 2021

Journal Articles

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood (2021) 138 (Supplement 1): 131.

https://doi.org/10.1182/blood-2021-145025

Published: 2021

Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140918

Published: 2020

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Heinz Ludwig, MD, Wolfram Pönisch, MD, Stefan Knop, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, MD PhD, Eberhard Gunsilius, MD, Karl Jochen Krenosz, MD, Andreas Petzer, MD, Katja Weisel, MD, Hermann Einsele, MD PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2018) 132 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2018-99-118061

Published: 2018

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Heinz Ludwig, MD, Wolfram Pönisch, MD, Alexander Egle, MD, Stefan Knop, MD, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, Eberhard Gunsilius, Michael A. Fridrik, MD, Andreas Petzer, MD, Katja C. Weisel, Dietger Niederwieser, MD, Axel Hinke, PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2017) 130 (Supplement 1): 1857.

https://doi.org/10.1182/blood.V130.Suppl_1.1857.1857

Published: 2017

Journal Articles

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Heinz Ludwig, MD, Eberhard Gunsilius, MD, Michael Fridrik, MD, Richard Greil, Andreas Petzer, MD, Thomas Kühr, Univ. Doz. Dr., Stefan Knop, MD, Martin Schreder, MD, Elisabeth Rauch, Mag., Wolfram Poenisch, MD, Niklas Zojer, MD

Blood (2016) 128 (22): 3335.

https://doi.org/10.1182/blood.V128.22.3335.3335

Published: 2016

Journal Articles

A Prospective Gene Expression Profiling Study for Prediction of Cytogenetic Response in Early and Late Chronic Phase CML.

Dominik Wolf, MD, Stefan U. Schmidt, MD, Dominik Fong, MD, Oliver Wrulich, PhD, Thomas Lion, MD, PhD, Florian Überall, PhD, Andreas Petzer, MD, Günther Gastl, MD

Blood (2007) 110 (11): 2916.

https://doi.org/10.1182/blood.V110.11.2916.2916

Published: 2007

Journal Articles

Planned First Efficacy and Safety Analysis of De-Intensified Induction with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos Study.

Alexander Egle, MD, Lukas Weiss, MD, Gudrun Russ, MD, Ralf Thoedtmann, MD, Lisa Pleyer, MD, Guenther Gastl, MD, Josef Thaler, MD, Andreas Petzer, MD, Inge Tinhofer, PhD, Richard Greil, MD

Blood (2007) 110 (11): 2045.

https://doi.org/10.1182/blood.V110.11.2045.2045

Published: 2007

Journal Articles

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.

Blood (2007) 110 (11): 1837.

https://doi.org/10.1182/blood.V110.11.1837.1837

Published: 2007

NARROW

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

A Prospective Gene Expression Profiling Study for Prediction of Cytogenetic Response in Early and Late Chronic Phase CML.

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only